EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial

Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao und 14 weitere

Annals of Hematology · 2024-07 · 103 (7) · 2273-2281

DOI: 10.1007/s00277-024-05826-5 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Annals of Hematology, online erschienen am 06.06.2024. Verfasst von Heng Mei und 25 weiteren Autor:innen. Beteiligte Einrichtung: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Pyrazoles, Benzoates, Purpura, Thrombocytopenic, Idiopathic, Hydrazines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While studies have explored the feasibility of switching between various thrombopoietin receptor agonists in treating immune thrombocytopenia (ITP), data on the switching from eltrombopag to hetrombopag remains scarce. This post-hoc analysis of a phase III hetrombopag trial aimed to assess the outcomes of ITP patients who switched from eltrombopag to hetrombopag. In the original phase III trial, patients initially randomized to the placebo group were switched to eltrombopag. Those who completed this 14-week eltrombopag were eligible to switch to a 24-week hetrombopag. Treatment response, defined as a platelet count of ≥ 50 × 10 9 /L, and safety were evaluated before and after the switch. Sixty-three patients who completed the 14-week eltrombopag and switched to hetrombopag were included in this post-hoc analysis. Response rates before and after the switch were 66.7% and 88.9%, respectively. Among those with pre-switching platelet counts below 30 × 10 9 /L, eight out of 12 patients (66.7%) responded, while eight out of nine patients (88.9%) with pre-switching platelet counts between 30 × 10 9 /L and 50 × 10 9 /L responded post-switching. Treatment-related adverse events were observed in 50.8% of patients during eltrombopag treatment and 38.1% during hetrombopag treatment. No severe adverse events were noted during hetrombopag treatment. Switching from eltrombopag to hetrombopag in ITP management appears to be effective and well-tolerated. Notably, hetrombopag yielded high response rates, even among patients who had previously shown limited response to eltrombopag. However, these observations need to be confirmed in future trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesBenzoatesPurpura, Thrombocytopenic, IdiopathicHydrazinesReceptors, ThrombopoietinPyrazolonesHumansMaleFemaleMiddle AgedAdultAgedDrug SubstitutionPlatelet CountTreatment OutcomeHydrazones

Stichwörter der Autor:innen

EltrombopagHetrombopagImmune thrombocytopeniaSwitchingThrombopoietin receptor agonist

Substanzen

eltrombopagPyrazolesBenzoatesHydrazinesReceptors, ThrombopoietinPyrazoloneshetrombopagHydrazones

Autor:innen und Institutionen

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, Hubei, China.
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.288 Nanjing Road Heping District, Tianjin, China.
  • West China Hospital, Sichuan University, No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China.
  • Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • The First Affiliated Hospital of Air Force Medical University, Xi'an, China.

Zitieren

APA

Mei, H., Liu, X., Li, Y., Zhou, H., Feng, Y., Gao, G., Cheng, P., Huang, R., Yang, L., Hu, J., Hou, M., Yao, Y., Liu, L., Wang, Y., Wu, D., Shen, X., Jin, J., Luo, J., Zeng, Y., …, & Hu, Y. (2024). Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial. Annals of Hematology, 103(7), 2273-2281. https://doi.org/10.1007/s00277-024-05826-5

Vancouver

Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, et al. Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial. Annals of Hematology. 2024;103(7):2273-2281. doi:10.1007/s00277-024-05826-5

BibTeX
@article{Mei2024,
  author = {Mei, Heng and Liu, Xiaofan and Li, Yan and Zhou, Hu and Feng, Ying and Gao, Guangxun and Cheng, Peng and Huang, Ruibin and Yang, Linhua and Hu, Jianda and Hou, Ming and Yao, Yazhou and Liu, Li and Wang, Yi and Wu, Depei and Shen, Xuliang and Jin, Jie and Luo, Jianmin and Zeng, Yun and Zhou, Xin and Xia, Ruixiang and Jiang, Zhongxing and Bai, Yuansong and Niu, Ting and Yang, Renchi and Hu, Yu},
  title = {Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial},
  journal = {Annals of Hematology},
  year = {2024},
  volume = {103},
  number = {7},
  pages = {2273--2281},
  doi = {10.1007/s00277-024-05826-5}
}
Kostenlos starten →